Study of Low Adherent Dressing Versus the Standard of Care for the Management of Skin Grafts Over Thermal Burns

Completed · Not applicable

Conditions studied: Burns, Skin Burn Requiring Skin Graft

In brief

The purpose of this study is to evaluate the P6 Low Adherent Study Dressing relative to the Standard of Care (SOC, Mafenide Acetate 5% Solution) for the management of skin grafts in burn wounds resulting from thermal burn injuries.

Key facts

Study ID

NCT01654094

Run by

Milliken Healthcare Products, LLC

People needed

80

Starts

2012-10-01

Expected to finish

2017-09-29

Last updated by the study team

2017-10-02

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must have thermal burns from scalds, flame/fire or contact with a hot object.
• Patients must have a TBSA burn of less than or equal to 50%.
• Patients must have two nonadjacent study burn sites (i.e., separated in such a way that SOC dressing does not contaminate the study dressing) of comparable size (up to approximately 2% TBSA) and severity requiring excision and grafting.
• Patients must have undergone excision and autografting on or before post-burn day (PBD) 14.
• Patients' study burn sites will be treated with skin grafts with a mesh ratio up to 3:1, at the surgeon's discretion.
• Patients expected to be available for assessment of study burn sites at least until POD 6 ±1 day.
• Males or females at least 18 years of age but no older than 65 years of age at the time of informed consent.
• Patient and / or Legally Authorized Representative (LAR) voluntarily agrees to provide written informed consent and the willingness and ability to comply with all aspects of the protocol.

You may not qualify if…

• Patients with electrical or chemical burns.
• Patients with a study burn site excised and "grafted" with Integra.
• Patients with study burn sites on the buttocks, scalp, hands, feet, neck or ears.
• Patients taking vasopressors or inotropes.
• Patients using systemic immunosuppressants (e.g., corticosteroids and anti-neoplastic agents, etc.).
• Patients with acute renal failure, defined as creatinine clearance (CrCL) >2.5 mg/dL or AKIN score greater than or equal to 2 or estimated GFR < 30, if the assessment is conducted as part of the patient's routine clinical care.
• Patients with acute respiratory distress syndrome (ARDS), if the assessment is conducted as part of the patient's routine clinical care.
• Patients with liver cirrhosis (Childs-Pugh B Class or greater) or who have AST / ALT levels greater than or equal to 2 times the upper limit of theinstitution's normal range, if the assessment is conducted as part of the patient's routine clinical care.
• Patients with a known sensitivity or known intolerance to mafenide acetate (Sulfamylon) or to silver.
• Patients with any concurrent medical condition, which in the opinion of the investigator, may compromise their safety or the objectives of the study.
• Patients who are breastfeeding, pregnant or expecting to become pregnant during the study..
• Patients who have been exposed to an investigational drug or device within 30 days prior to Screening or is scheduled to receive another investigational drug or device during either the Treatment Phase or Follow-up Evaluation.

Where it is running

• Shands at University of Florida — Gainesville, Florida, United States
• University of North Carolina, Chapel Hill — Chapel Hill, North Carolina, United States
• Wake Forest University Health Sciences — Winston-Salem, North Carolina, United States
• University of Tennessee Firefighter's Regional Burn Center — Memphis, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.